Detalhe da pesquisa
1.
Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719433
2.
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Mult Scler
; 30(2): 261-265, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38166437
3.
Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
Ann Neurol
; 87(2): 256-266, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725931
4.
Efficacy of rituximab in refractory RRMS.
Mult Scler
; 25(6): 828-836, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29722639
5.
Cortical Lesions as an Early Hallmark of Multiple Sclerosis: Visualization by 7 T MRI.
Invest Radiol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38889240
6.
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 11(3): e200231, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626360
7.
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception.
Neurol Neuroimmunol Neuroinflamm
; 10(5)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550074
8.
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
Neurol Neuroimmunol Neuroinflamm
; 10(5)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37604695
9.
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab.
Neurol Neuroimmunol Neuroinflamm
; 9(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34815322
10.
Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
Neurol Neuroimmunol Neuroinflamm
; 9(4)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35473885
11.
Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy.
Mult Scler J Exp Transl Clin
; 7(4): 20552173211062142, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34925877